GSK seeks FDA nod for expanded use of RSV vaccine in adults

GSK has submitted an application to the U.S. FDA to expand the use of its RSV vaccine, Arexvy, to at-risk adults under 50, positioning it to compete with Moderna's mRESVIA and Pfizer's Abrysvo in this demographic. This move is critical as Arexvy, currently approved for older adults, has experienced declining sales and lagged rivals, with a decision on the expansion expected by the first half of 2026.

Analysis

GSK has submitted an application to the U.S. FDA to expand the use of its RSV vaccine, Arexvy, to at-risk adults aged 18-49, a strategic move to enter a new demographic. This initiative is critical as the filing comes against a backdrop of deteriorating performance; the article explicitly states that Arexvy's sales have 'fallen sharply' and it has 'lagged behind rivals' in its currently approved market for older adults. If approved, GSK will face direct competition from Pfizer's Abrysvo and Moderna's mRESVIA, which are already positioned in the RSV market. The potential impact of this expansion is significantly delayed, with an FDA decision not expected until the first half of 2026. This extended timeline frames the application as a long-term effort to reverse market share erosion rather than a source of near-term growth.

Key Decisions for Investors

• Investors should treat this application as a long-dated call option on future revenue, as any financial contribution is contingent on a positive FDA decision not expected until H1 2026.
• The key risk to monitor is the ongoing market performance of Pfizer's and Moderna's competing vaccines, as their established presence could limit GSK's ability to gain meaningful share even if Arexvy is approved for the younger demographic.
• Focus should remain on Arexvy's current sales trajectory in the over-50 market, as the report of 'sharply' falling sales is a more immediate and material concern for GSK's fundamentals than this distant regulatory catalyst.